Objective
Allergies and asthma affect at least a quarter of the population and the WHO has declared allergy a major health problem of the 21st century. Currently, medical practitioners must pre-select very few allergens for in-vitro testing, based on prior anamnesis, under time and cost pressure. Independent experts estimate that almost half of the patients are diagnosed insufficiently. The consequences for the patients are not optimal treatment and reduced quality of life. For the public health systems more than 140 Bn Euro are spent each year which could be saved if all allergic patients were treated adequately. We have developed a multi-parameter allergy test covering close to 100% of the globally relevant allergens in a single lab test. Instead of forcing medical practitioners to pre-select very few allergens for in-vitro, our solution substantiates any
therapeutic decision by offering a complete immunological profile for every tested individual. We expand testing to the molecular level which provides valuable decision points such as enhanced risk assessment, improving the success of allergen immunotherapy or clearer recommendations for avoidance. We eliminate the trade-off between cost and quality of allergy diagnosis. Our allergy test is technically validated and registered as an in-vitro diagnostics device in Europe. We are already selling and delivering the non-automated manual test systems to customers all over Europe. In this project, we will fully automate the test instrumentation so we can target the customer segments of highly automated clinical routine labs. This will multiply our selling potential and expand our customer reach.
The global market of in-vitro diagnosis of allergy is growing fast at almost double-digit rate globally, and amounted to approx. 700 million USD annual revenues in 2016. There is a de-facto monopoly of a single US supplier and this project will return jobs and revenues to the European Union.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences health sciences public health
- medical and health sciences clinical medicine pneumology asthma
- social sciences sociology industrial relations automation
- medical and health sciences clinical medicine allergology
- medical and health sciences basic medicine immunology immunotherapy
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-2 - SME instrument phase 2
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1230 Wien
Austria
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.